Polyneuropathy In Hereditary Transthyretin Mediated Amyloidosis Therapeutics
1. Amvuttra patent expiration
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
AMVUTTRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(6 years from now) | |
| US11286486 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US10683501 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(2 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(3 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US10208307 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(6 years from now) | |
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US12049628 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| New Indication(I-964) | Mar 20, 2028 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Dosage: SOLUTION
More Information on Dosage
AMVUTTRA family patents
2. Onpattro patent expiration
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
ONPATTRO's oppositions filed in EPO
ONPATTRO IPR and PTAB Proceedings
Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9567582 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8895721 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8895718 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8372968 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8362231 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8552171 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(4 years ago) | |
| US8168775 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Aug, 2032
(6 years from now) | |
| US11079379 | ALNYLAM PHARMS INC | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(9 years from now) | |
| US10240152 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US8334373 | ALNYLAM PHARMS INC | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9193753 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(4 years ago) | |
| US8778902 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US9943539 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(2 years ago) | |
| US9943538 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(2 years ago) | |
| US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(4 years from now) | |
| US8822668 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(4 years from now) | |
| US8741866 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US9234196 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US11141378 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8642076 | ALNYLAM PHARMS INC | Lipid containing formulations |
Oct, 2027
(1 year, 8 months from now) | |
| US8492359 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| M(M-270) | Jan 13, 2026 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Dosage: SOLUTION
More Information on Dosage
ONPATTRO family patents
3. Tegsedi patent
expiration
Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis
TEGSEDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7015315 | AKCEA THERAPS | Gapped oligonucleotides |
Mar, 2023
(2 years ago) | |
| US7101993 | AKCEA THERAPS | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(2 years ago) | |
| US9061044 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(5 years from now) | |
| US8101743 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399774 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(5 years from now) | |
| US8697860 | AKCEA THERAPS | Diagnosis and treatment of disease |
Apr, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Dosage: SOLUTION
More Information on Dosage
TEGSEDI family patents